Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0L4ZK
|
||||
Former ID |
DIB012925
|
||||
Drug Name |
RG-7351
|
||||
Synonyms |
TAAR1 part agonist (depression), Roche; Trace amine-associated receptor 1 part agonist (depression), Roche
|
||||
Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Phase 1 | [549026] | ||
Company |
Roche Holding AG
|
||||
Target and Pathway | |||||
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Reactome | G alpha (s) signalling events | ||||
References | |||||
Ref 526471 | Methamphetamine increases the hippocampal alpha(2A)-adrenergic receptor and Galpha(o) in mice. Neurosci Lett. 2002 Dec 16;334(3):145-8. | ||||
Ref 526676 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003 Jul;86(2):413-21. | ||||
Ref 532175 | Involvement of the alpha(1D)-adrenergic receptor in methamphetamine-induced hyperthermia and neurotoxicity in rats. Neurotox Res. 2013 Aug;24(2):130-8. | ||||
Ref 532852 | Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. | ||||
Ref 551610 | Clinical pipeline report, company report or official report of Roche. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.